{
  "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583",
  "docSlug": "f06b0b5d2079",
  "documentTitle": "Soleno Therapeutics (SLNO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 386,
  "pageCount": 415,
  "prevPage": 385,
  "nextPage": 387,
  "slideType": "quote_slide",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide presents a Q&A format where the expert questions the company's motives and the clinical rationale for their product.",
  "elementsJson": [
    "paragraph",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/386",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-386",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.86,
        "x": 0.07,
        "y": 0.62
      },
      "kind": "callout",
      "text": "No reason to not use generic diazoxide suspension vs. Vykat; highly skeptical of arguments for Vykat vs. generic",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dd1ca864-21c3-444d-b5dd-c8088e8dae0b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "callout",
      "text": "I feel cynically or realistically, that they're marketing an extended-release to get a different drug so they can get the patent.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-70f3-714d-84c4-af8a39897f92",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "paragraph",
      "text": "The endocrinologist thinks generic diazoxide suspension is no different than Vykat and that the field will soon figure this out; that Soleno has provided no convincing answer for why its tablet formulation is necessary; that it is just a cynical patent ploy...",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1f53cef5-9aaf-47ea-8567-848aa94b1511",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.86,
        "x": 0.07,
        "y": 0.67
      },
      "kind": "quote",
      "text": "Q: \"If somebody is convinced by the diazoxide data and they like it, why wouldn't they just prescribe generic diazoxide suspension over the extended-release tablet? What's the rationale?\" A: \"So, this is the thing that is really a big question in my mind...\"",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0890698b-6dc0-4277-af0a-fe1f7aac9a22",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "So, this is the thing that is really a big question in my mind, because I don't really understand why — I haven't gotten a good answer, I don't feel like — why extended-release is necessary for this mechanism of action. And I feel cynically or realistically, that they're marketing an extended-release to get a different drug so they can get the patent. Why wouldn't I just be prescribing diazoxide? When I've asked other folks, they said diazoxide doesn't work. But in my mind, I'm just wondering if that's just they're bought and sold by the company to say that, to convince me not to prescribe diazoxide and prescribe Vykat. I feel like if I was to continue to have failure of getting this approved or other doctors would have failure getting this approved, I imagine that there would be more discussion around prescribing diazoxide liquid. And I'm just interested to see how that all plays out because I don't think that question has been answered to my satisfaction of exactly what you just asked me. Why aren't I just prescribing diazoxide? — Pediatric endocrinologist, leads one of the largest PWS clinics in US with 30-40 patients; 11 endocrinologists, major academic center",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-70f3-714d-84c4-b3796e2f826b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5cfac602-2a1e-42c0-973e-238370ad9199",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "0f37e050-e141-4d90-826c-49b006cf1c95",
      "evidence": "The slide explicitly frames the company's product strategy as a 'cynical patent ploy' and questions the integrity of proponents.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}